Early and easy-to-retrieve predictive biomarkers of resistance to immunotherapy in microsatellite instability (MSI)/mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC)

被引：0
|
作者：
Vaghi, C. [1 ]
Ros Montana, F. J. [2 ]
Mambrilla, M. [3 ]
Navarro Garces, V. [3 ]
Comas, R. [3 ]
Salva Ballabrera, F. [4 ]
Baraibar Argota, I. [5 ]
Saoudi Gonzalez, N. [5 ]
Rodriguez Castells, M. [2 ]
Garcia Rodriguez, A. [5 ]
Alcaraz, A. [6 ]
Tabernero, J. [2 ]
Elez Fernandez, M. E. [2 ]
机构：
[1] ASST Grande Osped Metropolitano Niguarda, Oncol Dept, Milan, Italy
[2] Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain
[3] Vall dHebron Inst Oncol VHIO, Oncol Data Sci Grp, Barcelona, Spain
[4] Vall dHebron Univ Hosp, Gastrointestinal Unit, Med Oncol, Barcelona, Spain
[5] Vall dHebron Univ Hosp, Dept Oncol, Barcelona, Spain
[6] Vall dHebron Univ Hosp, Colon Canc Dept, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.132
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
121P
引用
收藏
页码：S56 / S57
页数：2
相关论文
共 50 条
  • [1] Response to pembrolizumab in patients with mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC).
    Leal, Alexis Diane
    Paludo, Jonas
    Finnes, Heidi D.
    Grothey, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [2] On pembrolizumab (Keytruda) in microsatellite instability-high/mismatch repair deficient (MSI-h/MMRd) metastatic colorectal cancer (mCRC)
    Bekaii-Saab, Tanios S.
    ONCOLOGY-NEW YORK, 2021, 35 (07): : 380 - 380
  • [3] Biological and therapeutic impact of tumor mutational burden in microsatellite instability/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICI)
    Deverly, Sarah Blanchet
    Raffy, Balthazar
    Ratovomanana, Toky
    Nicolle, Remy
    Nay, Paula
    Andre, Thierry
    Duval, Alex
    Cohen, Romain
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 272 - 272
  • [4] Prevalence of NTRK1/3 fusions in mismatch repair-deficient (dMMR)/microsatellite instable (MSI) tumors of patients with metastatic colorectal cancer (mCRC).
    Svrcek, Magali
    Colle, Raphael
    Cayre, Anne
    Bourgoin, Pierre
    Cohen, Romain
    Andre, Thierry
    Penault-Llorca, Frederique Madeleine
    Radosevic-Robin, Nina
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] Predictive biomarkers for response to immunotherapy in patients with deficient DNA mismatch repair metastatic colorectal cancer.
    Stemmer, Amos
    Strauss, Gal
    Halpern, Naama
    Beller, Tamar
    Golan, Talya
    Margalit, Ofer
    Shacham-Shmueli, Einat
    Boursi, Ben
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 254 - 254
  • [6] KNOWLEDGE AND AWARENESS OF MISMATCH REPAIR/MICROSATELLITE INSTABILITY (MMR/MSI) TESTING AMONG US PATIENTS WITH ADVANCED/METASTATIC COLORECTAL CANCER (MCRC)
    Eriksson, J.
    Amonkar, M.
    Al-Jassar, G.
    Lambert, J.
    Malmenas, M.
    Chase, M.
    Sun, L.
    Kollmar, L.
    Vichnin, M.
    VALUE IN HEALTH, 2019, 22 : S110 - S110
  • [7] Pembrolizumab (pembro) for previously treated, microsatellite instabilityehigh (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): Final analysis of KEYNOTE-164
    Le, D. T.
    Diaz, L.
    Kim, T. W.
    Van Cutsem, E.
    Geva, R.
    Jager, D.
    Hara, H.
    Burge, M.
    O'Neil, B.
    Kavan, P.
    Yoshino, T.
    Guimbaud, R.
    Taniguchi, H.
    Elez, E.
    Al-Batran, S-E.
    Boland, P.
    Cui, Y.
    Leconte, P.
    Marinello, P.
    Andre, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S550 - S550
  • [8] Neoadjuvant chemo-immunotherapy in mismatch repair deficient (dMMR)/microsatellite instability (MSI) gastric carcinoma (GC): A multicenter retrospective study
    Sun, H.
    Moiseyenko, V.
    Chubenko, V.
    Gerk, I.
    Navmatulya, A.
    Shelekhova, K. V.
    Volkov, N. M.
    Zykov, E.
    Chernobrivceva, V.
    Nered, S.
    Besova, N.
    Obarevich, E.
    Gavrilova, D.
    Kononets, P.
    Stilidi, I.
    Belyak, N.
    Orlova, R. V.
    Topuzov, E.
    Pelipas, Y.
    Tryakin, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S180 - S181
  • [9] Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC).
    Andre, Thierry
    Shiu, Kai-Keen
    Kim, Tae Won
    Jensen, Benny Vittrup
    Jensen, Lars Henrik
    Punt, Cornelis J. A.
    Smith, Denis Michel
    Garcia-Carbonero, Rocio
    Alcaide, Julia
    Gibbs, Peter
    De la Fouchardiere, Christelle
    Rivera, Fernando
    Elez, Elena
    Bendell, Johanna C.
    Le, Dung T.
    Yoshino, Takayuki
    Zhong, Wen Yan
    Fogelman, David R.
    Marinello, Patricia
    Diaz, Luis A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] Quality of life (QoL) in patients (pts) with microsatellite instability (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) alone or in combination with ipilimumab (IPI): CheckMate 142
    Van Cutsem, E.
    Dixon, M.
    Taylor, F.
    Sun, X.
    Yip, C.
    Blum, S. I.
    ANNALS OF ONCOLOGY, 2021, 32 : S553 - S553
12345